CLS is committed to providing the media with timely and accurate information related to California’s life sciences ecosystem. CLS welcomes all media inquiries from news organizations and reporters. Members of the media interested in speaking with CLS opinion leaders on issues of public policy, life sciences innovation, or issues related to the life sciences ecosystem in California, please contact our communication department.
Media Contact: [email protected]
Mar 30, 2021
Hear about recent updates and innovations from our FAST and CARB-X Companies and CLSA Fellows Members.
Read More Mar 30, 2021
The CLSA-CLSI Racial & Social Equity (RSE) Initiative are debuting several new programs and events this summer, offering opportunities for industry professionals to engage with under-represented students and talent.
Read More Mar 30, 2021
As part of our ongoing programs to support early-stage companies, the Spring 2021 FAST Advisory Program just began, providing coaching and business advising for six startups.
Read More Mar 26, 2021
The California Life Sciences Association (CLSA) sponsored and introduced Assembly Bill (AB) 593, with Assemblymember Cottie Petrie-Norris (AD 74) which reinstates the Research and Development (R&D) Tax Credit and Net Operating Loss (NOL) deductions for life sciences companies in California for tax years 2021 and 2022.
Read More Mar 24, 2021
CLSA’s diverse membership base of life sciences companies and organizations grows each month as we welcome the world’s most promising entrepreneurial start-ups, research institutions, investors and the full spectrum of life sciences, therapeutics, medical device and diagnostic companies that are addressing global health challenges; digital health innovators that are using technology to transform healthcare; agricultural companies improving the safety and security of our food supply; and bioindustrial organizations energizing a more sustainable world.
Read More Mar 24, 2021
Biocom California and the California Life Sciences Association (CLSA) today released data analyzing the potential impact of international reference pricing (foreign price controls) on California’s biopharmaceutical innovation ecosystem, including investment into small company capital formation and the new drug development pipeline.
Read More